Theravance Biopharma, Inc. (TBPH) Shares Sold by NJ State Employees Deferred Compensation Plan

NJ State Employees Deferred Compensation Plan cut its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 51.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,142 shares of the biopharmaceutical company’s stock after selling 25,142 shares during the quarter. NJ State Employees Deferred Compensation Plan’s holdings in Theravance Biopharma were worth $827,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Parametric Portfolio Associates LLC boosted its stake in Theravance Biopharma by 1.5% during the second quarter. Parametric Portfolio Associates LLC now owns 14,307 shares of the biopharmaceutical company’s stock worth $570,000 after acquiring an additional 217 shares in the last quarter. Ameritas Investment Partners Inc. boosted its stake in Theravance Biopharma by 6.3% during the second quarter. Ameritas Investment Partners Inc. now owns 3,865 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 230 shares in the last quarter. SG Americas Securities LLC boosted its stake in Theravance Biopharma by 8.1% during the second quarter. SG Americas Securities LLC now owns 5,931 shares of the biopharmaceutical company’s stock worth $236,000 after acquiring an additional 443 shares in the last quarter. Legal & General Group Plc boosted its stake in Theravance Biopharma by 3.7% during the second quarter. Legal & General Group Plc now owns 16,289 shares of the biopharmaceutical company’s stock worth $649,000 after acquiring an additional 576 shares in the last quarter. Finally, Zacks Investment Management boosted its stake in Theravance Biopharma by 4.6% during the second quarter. Zacks Investment Management now owns 21,603 shares of the biopharmaceutical company’s stock worth $861,000 after acquiring an additional 959 shares in the last quarter. 84.86% of the stock is currently owned by institutional investors and hedge funds.

In related news, CEO Rick E. Winningham acquired 10,000 shares of Theravance Biopharma stock in a transaction on Friday, August 11th. The shares were acquired at an average cost of $24.50 per share, with a total value of $245,000.00. Following the transaction, the chief executive officer now owns 866,377 shares in the company, valued at $21,226,236.50. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Bradford J. Shafer sold 14,670 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $30.77, for a total transaction of $451,395.90. Following the transaction, the executive vice president now directly owns 134,327 shares in the company, valued at $4,133,241.79. The disclosure for this sale can be found here. Over the last three months, insiders have acquired 20,000 shares of company stock worth $494,300. Insiders own 6.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Theravance Biopharma, Inc. (TBPH) Shares Sold by NJ State Employees Deferred Compensation Plan” was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/02/theravance-biopharma-inc-tbph-shares-sold-by-nj-state-employees-deferred-compensation-plan.html.

Several research analysts recently issued reports on the stock. Cantor Fitzgerald set a $55.00 target price on shares of Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Evercore ISI assumed coverage on shares of Theravance Biopharma in a research note on Wednesday, August 16th. They set an “outperform” rating and a $45.00 target price on the stock. Zacks Investment Research raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, September 19th. Robert W. Baird reissued a “sell” rating and set a $22.00 target price on shares of Theravance Biopharma in a research note on Wednesday. Finally, BidaskClub lowered shares of Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Four analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $41.86.

About Theravance Biopharma

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

What are top analysts saying about Theravance Biopharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Theravance Biopharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit